Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
54
NCT05242822
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 29, 2022
Completion: Oct 3, 2024